Registered | 44 (59%) |
Funding | Â |
 Industry | 54 (73%) |
  Government | 4 (5%) |
  Institution | 2 (3%) |
  Not-for-profit | 0 (0%) |
  None | 1 (1%) |
  Not reported | 13 (17%) |
 Mean age | 41 |
 Male (%) | 16% |
 Migraine with aura (%) | 18 (45%) |
 Prior prophylaxis (%) | 28 (49%) |
 Mean migraine days/month | 11 |
 Interventions | |
 Amitriptyline | 7 (10%) |
  Beta-blockers | 13 (18%) |
  Calcium Channel Blockers | 8 (11%) |
  Carismabate | 2 (3%) |
  Eptinezumab | 5 (7%) |
  Erenumab | 9 (13%) |
  Fremanezumab | 7 (10%) |
  Gabapentin | 2 (3%) |
  Galcanezumab | 7 (10%) |
  Gepants | 4 (6%) |
  Oxcarbazepine | 1 (1%) |
  Pregabalin | 1 (1%) |
  Topiramate | 13 (18%) |
  Valproate | 8 (11%) |